AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

IASO-782 in Autoimmune Hematological Diseases

RecruitingPhase 1Ages 18 Years - 65 YearsAllShanghai IASO Biotechnology Co., Ltd
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with autoimmune hematological diseases. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of autoimmune haematological diseases (ITP and wAIHA).

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Age 18-65 years 2. Clinically confirmed diagnosis of autoimmune thrombocytopenia (ITP) or warm autoimmune haemolytic anaemia (wAIHA) 3. Failure or relapse after at least 1 treatment for the study disease 4. Stable dose of immunosuppressants for 4 weeks before screening 5. Organ function or laboratory test is basically normal 6. Subjects of childbearing potential and their partners must use effective contraception for at least 2 weeks before administration of investigational product, throughout the trial period, and for 28 days after the end of the trial (or early termination of the trial) 7. Females of potential childbearing capacity must have a negative pregnancy test at screening 8. Voluntarily participate in this study and sign the informed consent Exclusion Criteria: 1. History of other primary malignant neoplasm within 5 years of screening 2. Secondary to other disease-induced hematopoietic destruction 3. Cardiac disorder within the last 3 months 4. Patients with high blood pressure that cannot be controlled by drug 5. Subjects with a history of allergy to any component of the investigational drug 6. Active infection requiring intravenous treatment within 30 days prior to the enrollment 7. Pregnant or breastfeeding women 8. Participation was being given other investigational drug within 30 days or 5 half-lives (whichever is longer) prior to administration of the investigational drug 9. Previous treatment drugs have not been adequately washed out 10. ITP patients have had any previous arterial or venous thrombosis 11. Patients with ITP had previous biopsy bone marrow results indicating bone marrow fibrosis (Myelofibrosis MF) โ‰ฅ 2 12. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol 13. Subjects with a history of drug abuse or mental disorder 14. Other medical history or conditions that would make the subject unsuitable for the study by investigators' judge.
๐Ÿ’Š

What it tests

  • IASO-782 injection
  • placebo
๐Ÿ“

Where

2 sites
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Institute of Hematology, Chinese Academy of Medical Sciences
Tianjin, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy